Sign in
Download Opera News App



Health COVID


Novavax to start mid-stage study of its experimental COVID-19 vaccine in South Africa

The United States (US) drug developer Novavax said it would start a mid-stage study of its experimental COVID-19 vaccine in South Africa, this is the second vaccine being tested in South Africa.

The trial which is said to be in phase 2B will conduct trials on about 2 600 healthy people, specifically, adults and will evaluate the safety, efficiency and immunity of 249 medically stable HIV positive adults as well.

Since South Africa was in its winter season and experiencing a winter surge of infections, Novavax research chief Gregory Glen said that the trial has the potential to provide an early indication of efficacy.

Currently, South Africa is the fifth-worst affected country with 583,000 coronavirus cases and 18 000 fatalities. The president took the country to level 2 in a brief speech last night. This has a risk of surging cases again but the good thing is that many more industries, businesses and jobs will reopen and the country will be taking a step further into recovery. 

Content created and supplied by: Traysee (via Opera News )

Gregory Glen HIV Novavax South Africa United States


Load app to read more comments